Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has shared an update.
On April 16, 2026, Pulse Biosciences posted an updated investor presentation detailing its pivotal clinical study of the nsPFA Cardiac Catheter for atrial fibrillation, its next‑generation nPulse cardiac catheter under development, and its 2026 corporate goals across electrophysiology, cardiac surgery and soft tissue ablation. By outlining its clinical and product development roadmap and strategic objectives, the company signaled how it plans to advance its cardiac ablation portfolio and execute on its 2026 operating priorities, information that will now guide communications with investors and analysts.
The most recent analyst rating on (PLSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by very weak financial performance (minimal revenue, large losses, and accelerating cash burn). Offsetting this, the earnings narrative and recent corporate updates show meaningful clinical/regulatory progress that could improve the outlook if trials and commercialization milestones are met, while technicals remain soft in the near term and valuation signals are not supportive due to ongoing losses.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a medical technology company focused on developing and commercializing cardiac ablation tools, including its nsPFA Cardiac Catheter, for the treatment of atrial fibrillation and other applications in electrophysiology, cardiac surgery and soft tissue ablation. The company targets physicians, hospitals and clinical centers involved in advanced cardiac and soft tissue procedures.
Average Trading Volume: 352,231
Technical Sentiment Signal: Buy
Current Market Cap: $1.34B
For an in-depth examination of PLSE stock, go to TipRanks’ Overview page.